RU2003124660A - Способ производства комбинированной вакцины - Google Patents
Способ производства комбинированной вакцины Download PDFInfo
- Publication number
- RU2003124660A RU2003124660A RU2003124660/15A RU2003124660A RU2003124660A RU 2003124660 A RU2003124660 A RU 2003124660A RU 2003124660/15 A RU2003124660/15 A RU 2003124660/15A RU 2003124660 A RU2003124660 A RU 2003124660A RU 2003124660 A RU2003124660 A RU 2003124660A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- combined
- amount
- pertussis
- adsorbent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (13)
1. Способ производства комбинированной вакцины, включающий в себя следующие стадии:
стадию адсорбции, при которой каждый защитный антиген, соответствующий тому или иному заболеванию, независимо адсорбируется на адсорбенте, и
стадию смешивания каждого указанного защитного антигена, адсорбированного на адсорбенте.
2. Способ по п.1, где защитный антиген представляет собой антиген, выбранный из группы, включающей в себя дифтерийный антиген, столбнячный антиген, коклюшный антиген, антиген гепатита В, или две или более их комбинации.
3. Способ по п.1, где адсорбент представляет собой гель гидроксида алюминия.
4. Способ по п.3, где концентрация ионов алюминия в геле гидроксида алюминия после производства комбинированной вакцины заключена в пределах 0,5-1,25 мг/мл.
5. Способ по п.3 или 4, дополнительно включающий в себя стадию добавления адсорбента, причем конечная концентрация ионов алюминия в геле гидроксида алюминия не выходит за пределы 0,5-1,25 мг/мл.
6. Способ по п.2, где рекомбинантный поверхностный антиген гепатита В комбинируют в количестве 5-10 мкг, на основе педиатрической дозы.
7. Способ по п.6, дополнительно включающий в себя стадию добавления нейтрального поверхностно-активного вещества, такого как Полисорбат 20, Полисорбат 80 и Тритон Х-100.
8. Способ по п.6, где указанный антиген гепатита В смешивают путем взбалтывания с абсорбентом при 2-8°С в течение 3-20 часов, подвергают созреванию и адсорбируют.
9. Способ по п.2, где дифтерийный анатоксин, обезвреженный в качестве дифтерийного антигена, комбинируют в количестве 10-25 Lf, на основе педиатрической дозы.
10. Способ по п.2, где столбнячный анатоксин, обезвреженный в качестве столбнячного антигена, комбинируют в количестве 1-5 Lf, на основе педиатрической дозы.
11. Способ по п.2, где коклюшный антиген, включающий в себя очищенные антигены, комбинируют в количестве менее 20 мкгPN, на основе педиатрической дозы, или цельноклеточный коклюшный антиген комбинируют в количестве менее 20 ОЕ, на основе педиатрической дозы.
12. Способ по п.11, где указанные очищенные коклюшные антигены включают в себя коклюшный анатоксин и FHA (волокнистый гемагглютинин).
13. Комбинированная вакцина, изготовленная согласно любому из способов по пп.1-12.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2001-0001290A KR100401423B1 (ko) | 2001-01-10 | 2001-01-10 | 혼합 백신의 제조 방법 |
| KR2001-0001290 | 2001-01-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003124660A true RU2003124660A (ru) | 2005-01-10 |
| RU2264226C2 RU2264226C2 (ru) | 2005-11-20 |
Family
ID=19704448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003124660/15A RU2264226C2 (ru) | 2001-01-10 | 2002-01-09 | Способ производства комбинированной вакцины |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20040048336A1 (ru) |
| EP (1) | EP1349572B1 (ru) |
| JP (1) | JP3977257B2 (ru) |
| KR (1) | KR100401423B1 (ru) |
| CN (1) | CN1228086C (ru) |
| AR (1) | AR032391A1 (ru) |
| AT (1) | ATE373485T1 (ru) |
| AU (1) | AU2002219693B2 (ru) |
| BR (1) | BR0206391A (ru) |
| CA (1) | CA2434421C (ru) |
| DE (1) | DE60222529T2 (ru) |
| ES (1) | ES2291466T3 (ru) |
| IL (1) | IL156791A0 (ru) |
| MX (1) | MXPA03006154A (ru) |
| MY (1) | MY143688A (ru) |
| PE (1) | PE20020758A1 (ru) |
| PL (1) | PL211005B1 (ru) |
| RU (1) | RU2264226C2 (ru) |
| UY (1) | UY27118A1 (ru) |
| WO (1) | WO2002055105A1 (ru) |
| ZA (1) | ZA200305072B (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69319728T2 (de) | 1992-05-23 | 1999-02-04 | Smithkline Beecham Biolog | Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten |
| GB0505996D0 (en) | 2005-03-23 | 2005-04-27 | Glaxosmithkline Biolog Sa | Fermentation process |
| GB0522765D0 (en) * | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
| CA2654014A1 (en) * | 2006-05-31 | 2007-12-06 | Silvio Buzzi | Pharmaceutical use of protein molecules immunologically correlated to diphtheria toxin |
| GB0616306D0 (en) * | 2006-08-16 | 2006-09-27 | Novartis Ag | Vaccines |
| PT2097102E (pt) * | 2006-09-07 | 2012-08-03 | Glaxosmithkline Biolog Sa | Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus |
| GB0822633D0 (en) * | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| IT1398927B1 (it) | 2009-06-25 | 2013-03-28 | Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi | Espressione batterica di un gene artificiale per la produzione di crm197 e derivati. |
| GB0917647D0 (en) | 2009-10-08 | 2009-11-25 | Glaxosmithkline Biolog Sa | Expression system |
| CN102363041A (zh) * | 2011-11-17 | 2012-02-29 | 成都欧林生物科技股份有限公司 | 不含防腐剂疫苗的制作工艺 |
| KR101518473B1 (ko) | 2013-03-14 | 2015-05-07 | (주)바이오인디스트 | 애완견의 바이러스성 전염병 예방 및 치료용 복합 난황 항체 조성물 및 그 제조방법 |
| AR102548A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso |
| AR102547A1 (es) * | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
| WO2022114921A1 (ko) * | 2020-11-30 | 2022-06-02 | 주식회사 엘지화학 | 알루미늄 부형제를 이용하여 다가 혼합백신 내 백일해 균 유래 엔도톡신 제거 방법 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU188847B (en) * | 1983-02-22 | 1986-05-28 | Human Oltoanyagtermeloe Es Kutato Intezet,Hu | Process for producing liophylized combined vaccines |
| CA1213234A (en) * | 1983-03-30 | 1986-10-28 | Akihiro Ginnaga | Method for the production of ha fraction containing protective antigens of bordetella pertussis and pertussis vaccine |
| US4649192A (en) * | 1985-05-30 | 1987-03-10 | Smith Kline-Rit | Method for the isolation and purification of hepatitis B surface antigen using polysorbate |
| EP0251575B2 (en) * | 1986-06-17 | 2002-11-13 | Chiron Corporation | Hepatitis delta diagnostics and vaccines, their preparation and use |
| JPH085804B2 (ja) * | 1988-04-28 | 1996-01-24 | 財団法人化学及血清療法研究所 | Ａ型及びｂ型肝炎混合アジュバントワクチン |
| EP0484621A3 (en) * | 1990-07-11 | 1992-08-26 | American Cyanamid Company | Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens |
| DE69319728T2 (de) * | 1992-05-23 | 1999-02-04 | Smithkline Beecham Biolog | Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten |
| US6372225B1 (en) * | 1996-03-23 | 2002-04-16 | The Research Foundation Of Microbial Diseases Of Osaka University | Tetanus toxin functional fragment antigen and tetanus vaccine |
| GB9611501D0 (en) * | 1996-06-03 | 1996-08-07 | Smithkline Beecham Biolog | Vaccine compositions |
| CA2259415A1 (en) * | 1996-07-02 | 1998-01-08 | Connaught Laboratories Limited | Multivalent dtp-polio vaccines |
| GB9623233D0 (en) * | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
| BR9714980A (pt) * | 1997-09-15 | 2001-11-06 | Pasteur Merieux Msd | Vacinas multivalentes |
| GB9806456D0 (en) * | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
-
2001
- 2001-01-10 KR KR10-2001-0001290A patent/KR100401423B1/ko active IP Right Grant
-
2002
- 2002-01-08 MY MYPI20020056A patent/MY143688A/en unknown
- 2002-01-09 AR ARP020100060A patent/AR032391A1/es unknown
- 2002-01-09 AU AU2002219693A patent/AU2002219693B2/en not_active Ceased
- 2002-01-09 BR BR0206391-3A patent/BR0206391A/pt active Search and Examination
- 2002-01-09 CN CNB028035933A patent/CN1228086C/zh not_active Expired - Fee Related
- 2002-01-09 ES ES02729589T patent/ES2291466T3/es not_active Expired - Lifetime
- 2002-01-09 US US10/465,930 patent/US20040048336A1/en not_active Abandoned
- 2002-01-09 MX MXPA03006154A patent/MXPA03006154A/es active IP Right Grant
- 2002-01-09 PL PL369433A patent/PL211005B1/pl not_active IP Right Cessation
- 2002-01-09 DE DE60222529T patent/DE60222529T2/de not_active Revoked
- 2002-01-09 UY UY27118A patent/UY27118A1/es not_active IP Right Cessation
- 2002-01-09 EP EP02729589A patent/EP1349572B1/en not_active Revoked
- 2002-01-09 WO PCT/KR2002/000034 patent/WO2002055105A1/en active IP Right Grant
- 2002-01-09 RU RU2003124660/15A patent/RU2264226C2/ru active
- 2002-01-09 CA CA2434421A patent/CA2434421C/en not_active Expired - Fee Related
- 2002-01-09 AT AT02729589T patent/ATE373485T1/de not_active IP Right Cessation
- 2002-01-09 JP JP2002555838A patent/JP3977257B2/ja not_active Expired - Fee Related
- 2002-01-09 PE PE2002000008A patent/PE20020758A1/es active IP Right Grant
-
2003
- 2003-01-09 IL IL15679103A patent/IL156791A0/xx not_active IP Right Cessation
- 2003-06-30 ZA ZA200305072A patent/ZA200305072B/en unknown
-
2009
- 2009-03-19 US US12/407,445 patent/US20090181050A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR032391A1 (es) | 2003-11-05 |
| UY27118A1 (es) | 2002-08-30 |
| ZA200305072B (en) | 2003-09-17 |
| CA2434421A1 (en) | 2002-07-18 |
| RU2264226C2 (ru) | 2005-11-20 |
| AU2002219693B2 (en) | 2006-03-16 |
| DE60222529T2 (de) | 2008-06-19 |
| US20040048336A1 (en) | 2004-03-11 |
| DE60222529D1 (de) | 2007-10-31 |
| MXPA03006154A (es) | 2003-09-16 |
| ATE373485T1 (de) | 2007-10-15 |
| PL369433A1 (en) | 2005-04-18 |
| JP2004517866A (ja) | 2004-06-17 |
| EP1349572A1 (en) | 2003-10-08 |
| PE20020758A1 (es) | 2002-08-29 |
| BR0206391A (pt) | 2004-07-27 |
| CA2434421C (en) | 2012-02-21 |
| EP1349572B1 (en) | 2007-09-19 |
| EP1349572A4 (en) | 2004-09-15 |
| MY143688A (en) | 2011-06-30 |
| KR20020060298A (ko) | 2002-07-18 |
| PL211005B1 (pl) | 2012-03-30 |
| CN1484531A (zh) | 2004-03-24 |
| CN1228086C (zh) | 2005-11-23 |
| ES2291466T3 (es) | 2008-03-01 |
| US20090181050A1 (en) | 2009-07-16 |
| JP3977257B2 (ja) | 2007-09-19 |
| KR100401423B1 (ko) | 2003-10-17 |
| IL156791A0 (en) | 2004-02-08 |
| WO2002055105A1 (en) | 2002-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003124660A (ru) | Способ производства комбинированной вакцины | |
| JP5559847B2 (ja) | ワクチンに使用するためのｈｂｖ抗原の精製 | |
| US4997915A (en) | Purification of pertussis toxins | |
| HU227613B1 (en) | Vaccine composition | |
| RU2011120308A (ru) | Комбинированная вакцина с ацеллюлярным коклюшем | |
| RU99101850A (ru) | Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно(акдс)-полиомиелитные вакцины | |
| IL145982A0 (en) | Vaccines | |
| MY133780A (en) | Vaccine composition | |
| JP2015509522A5 (ru) | ||
| CA2188284A1 (en) | Group a streptococcal polysaccharide immunogenic compositions and methods | |
| JP2004505992A5 (ru) | ||
| WO2002032923A3 (en) | Improved formulations using heat shock/stress protein-peptide complexes | |
| WO2003082329A3 (en) | Compositions and compounds for use as molecular adjuvant for a nicotine vaccine | |
| WO2003080111A3 (en) | Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof | |
| JP2007513992A5 (ru) | ||
| AU2002219693A1 (en) | Manufacturing method of combined vaccine | |
| DE69636527D1 (de) | Antigenes protein aus malassezia | |
| RU2130778C1 (ru) | Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша | |
| WO2005117956A3 (en) | Neisserial vaccines | |
| DE60033291D1 (de) | Multi-komponenten impfstoff zum schutz vor krankheiten die durch haemophilus influenza und moxarella catarrhalis ausgelöst werden | |
| KR20010043224A (ko) | 백신 조성물 | |
| RU2001129663A (ru) | Вакцина против ящура типа О и способ ее изготовления | |
| TH61084A (th) | วิธีการผลิตวัคซีนรวม | |
| WO2002004497A3 (en) | Multiple antigenic peptides immunogenic against streptococcus pneumoniae | |
| Kholodok et al. | Etiological characterization clinic and epidemiology of a cluster respiratory infection among children in the Khabarovsk territory |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner | ||
| PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20180213 |